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P-glycoproteina b s t r a c t
Controlled release (CR) formulations are usually designed to achieve similar exposure (AUC) levels as the
marketed immediate release (IR) formulation. However, the AUC is often lower following CR compared to
IR formulations. There are a few exceptions when the CR formulations have shown higher AUC. This study
investigated the impact of CR formulations on oral drug absorption and CYP3A4-mediated gut wall metab-
olism. A review of the current literature on relative bioavailability (Frel) between CR and IR formulations of
CYP3A substrates was conducted. This was followed by a systematic analysis to assess the impact of the
release characteristics and the drug-speciﬁc factors (including metabolism and permeability) on oral bio-
availability employing a physiologically-based pharmacokinetic (PBPK) modelling and simulation
approach. From the literature review, only three CYP3A4 substrates showed higher Frel when formulated
as CR. Several scenarios were investigated using the PBPK approach; inmost of them, the oral absorption of
CR formulations was lower as compared to the IR formulations. However, for highly permeable com-
pounds that were CYP3A4 substrates the reduction in absorption was compensated by an increase in
the fraction that escapes from ﬁrst pass metabolism in the gut wall (FG), where the magnitude was depen-
dent on CYP3A4 afﬁnity. The systematic simulations of various interplays between different parameters
demonstrated that BCS class 1 highly-cleared CYP3A4 substrates can display up to 220% higher relative
bioavailability when formulated as CR compared to IR, in agreement with the observed data collected from
the literature. The results and methodology of this study can be employed during the formulation devel-
opment process in order to optimize drug absorption, especially for CYP3A4 substrates.
 2014 The Authors. Published by Elsevier B.V. This is anopenaccess article under the CCBY license (http://
creativecommons.org/licenses/by/3.0/).1. Introduction
The magnitude of oral drug absorption and systemic availability
are consequences of the interplay between parameters related to
the drug itself, drug product (formulation), study condition and
the system, i.e., the human body. Hence, drug-speciﬁc physico-
chemical and biopharmaceutical characteristics, together with
anatomical and physiological factors, will determine a drug’s oral
bioavailability (F) in a given scenario. F is the product of the frac-
tion of the drug that is absorbed (fa) and the fractions that escapefrom pre-systemic metabolism in both the gut wall (FG) and the
liver (FH) (Lin et al., 1999).
Formulation characteristics can play a critical role in the drug
absorption process. This applies in particular for drugs for which
dissolution, solubility and/or permeability characteristics repre-
sent the limiting steps for oral absorption, namely, drugs that do
not belong to class 1 in the Biopharmaceutics Classiﬁcation System
(BCS) (Amidon et al., 1995; Wilding, 1999). The BCS deﬁnes four
classes based on a compound’s aqueous solubility and intestinal
permeability (high solubility and high permeability (class 1), low
solubility and high permeability (class 2), high solubility and low
permeability (class 3), low solubility and low permeability (class
4)) (Amidon et al., 1995). In general, the selection of a speciﬁc for-
mulation is based on its minimal negative impact on the drug
absorption rate, i.e., immediate release (IR) formulations. However,
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the drug from the formulation into the gastrointestinal (GI) lumen
is desirable (Langer, 1990). Hence, understanding the potential
kinetics of oral absorption for the so-called controlled release
(CR) dosage forms and the prediction of their behaviour based on
in vitro information is valuable.
CR formulations provide certain advantages when compared to
their IR counterparts. CR formulations can reduce peak to trough
ﬂuctuations in the plasma concentration–time proﬁle (compared
to multiple-dose administration of an IR product), hence reducing
ﬂuctuation-related side effects and/or sub-therapeutic concentra-
tions. CR formulations can increase the exposure over time of drugs
with a short elimination half-life, and can be used to target deliv-
ery into distal regions of the intestine (e.g. colon), or where there is
a need for targeted delivery for the treatment of a speciﬁc disease,
such has Crohn’s disease (Langer, 1990; Rubinstein, 2005;
Thombre, 2005). This can lead to an increased patient compliance.
Furthermore, CR formulations can be of use in drug development
when the standard IR formulation is not an alternative due to unfa-
vourable pharmacokinetic properties of the drug candidate
(Langer, 1990; Rubinstein, 2005; Thombre, 2005).
One of the main goals when developing a CR formulation of a
marketed drug is to achieve, at least, the same exposure as the
equivalent dose of their IR counterpart. In general however the rel-
ative bioavailability of a CR formulation compared to its IR coun-
terpart is expected to be less than 100% (European Medicines
Agency, 2013). Several physiological factors can inﬂuence the
observed differences in systemic exposure between IR and CR. A
CR formulation is intended to release its drug content within 12–
24 h, in contrast the small intestinal transit time is around 2–5 h
(Davis et al., 1986; Fallingborg et al., 1989; Yu et al., 1996). There-
fore a majority of the dose should be released into distal regions of
the small intestine and the colon, where the residence time in the
colon is about 12–24 h (Coupe et al., 1992; Davis et al., 1986;
Fallingborg et al., 1989). The extended release may limit the
absorption potential for a drug formulated as CR as, in general,
the distal regions of the intestine provide a less favourable envi-
ronment for drug absorption. For instance, the reduced surface
area available for absorption in the distal region of the GI tract
may limit the absorption for poorly permeable compounds
(Tannergren et al., 2009; Watts and Lllum, 1997), the intestinal
pH increases towards the distal portion of the intestine conse-
quently limiting the aqueous solubility of basic compounds
(Fallingborg et al., 1989). Finally, the lack of bile salts, less ﬂuid vol-
ume in the colon, differences in the regional permeability and pos-
sible degradation by colonic microﬂora can also have a negative
impact on the drug absorption of CR formulations (Lennernas,
2014a; Schiller et al., 2005; Sutton, 2009; Tannergren et al., 2009).
Regardless of the unfavourable conditions for the absorption in
the distal regions of the GI tract, there are a few examples in the
literature were CR formulations of a marketed drug can display
higher relative bioavailability compared to their IR formulations.
For instance, a single-dose study of a CR formulation of buspirone
(5-hydroxytryptamine 1A (5-HT) partial agonist) showed a relative
bioavailability of 170–190% as compared to a similar dose of an IR
formulation (Sakr and Andheria, 2001b) producing an almost 3.3-
fold higher exposure at steady-state (Sakr and Andheria, 2001a).
For oxybutynin (anticholinergic), the CR formulation displayed a
relative bioavailability of 153% as compared to the IR formulation
(Gupta and Sathyan, 1999). Additional studies have showed that
the CR formulation of oxybutynin signiﬁcantly reduced the anti-
cholinergic side-effects of oxybutynin as compared to the IR for-
mulation, without reducing the efﬁcacy of oxybutynin for the
treatment of urinary incontinency (Comer and Goa, 2000; Gupta
et al., 1999; Sathyan et al., 2001).Despite almost complete absorption, both buspirone and oxy-
butynin display an oral bioavailability of around 4% and 6%, respec-
tively, due to extensive ﬁrst-pass metabolism in the gut wall and
liver (Douchamps et al., 1988; Gammans et al., 1985; Lukkari
et al., 1998; Mizushima et al., 2007; Yaich et al., 1998; Zhu et al.,
2005). Cytochrome P450 (CYP) 3A4 is believed to be the main
enzyme responsible for the metabolism of oxybutynin and buspi-
rone (Douchamps et al., 1988; Gammans et al., 1985; Lukkari
et al., 1998; Mizushima et al., 2007; Yaich et al., 1998; Zhu et al.,
2005). Therefore it has been hypothesized that the observed differ-
ences between CR and IR formulations are a consequence of the
distribution pattern of CYP3A along the small intestine (Gupta
and Sathyan, 1999; Sakr and Andheria, 2001a,2001b; Tubic-
Grozdanis et al., 2008). The abundance of CYP3A varies along the
membrane of the small intestine, being higher in the upper region
and decreasing towards the distal region and colon (Berggren et al.,
2007; Paine et al., 1997; Zhang et al., 1999). Therefore, the CR for-
mulation of such drugs would release most of its drug content into
intestinal regions with a lower abundance of CYP3A, thus poten-
tially bypassing the CYP3A-mediated ﬁrst pass metabolism. This
hypothesis is supported by an observed reduction in the exposure
of the metabolites of both buspirone and oxybutynin when admin-
istered as a CR formulation vs. their IR formulations (Gupta and
Sathyan, 1999; Sakr and Andheria, 2001a,2001b). The reduction
in exposure of oxybutynin’s metabolite, N-desethyloxybutynin,
could also explain the reported improvements in the safety proﬁle
of oxybutynin when formulated as a CR (Gupta et al., 1999;
Sathyan et al., 2001).
Despite the fact that clinical evidence might support the afore-
mentioned hypothesis, there are no clear indications whether this
higher relative bioavailability would be observable for all CYP3A
substrates when formulated as CR. Due to the complex relationship
between absorption and ﬁrst pass metabolism in the GI tract
(Darwich et al., 2010) it might prove difﬁcult to differentiate the
main driving forces behind this observed phenomenon, i.e., colonic
absorption window vs. a decreased gut wall metabolism in the
colon, or both (Tannergren et al., 2009). To our knowledge however
there is a paucity of studies investigating these bioavailability dif-
ferences in a prospective manner. In addition, no attempts have
been made to either elucidate the drug and formulation properties
associated with the occurrence of such phenomenon or to correlate
its magnitude to the aforementioned drug’s physicochemical, bio-
pharmaceutical and biochemical properties.
Due to the multifactorial nature of the problem, modelling and
simulation (M&S), in particular physiologically-based pharmacoki-
netic (PBPK) M&S, can be useful for the prospective analysis of the
impact of such properties on the absorption and ﬁrst past metabo-
lism of CR formulations of CYP3A substrates. In silico PBPK models
integrate current knowledge of both the system, i.e., morphophys-
iological factors (and their population characteristics) and drug
properties that may inﬂuence oral drug absorption (Jamei et al.,
2009c). This approach has the advantage to allow the theoretical
exploration of the interplay between the system and the drug
properties and therefore hypothesize on the main driving forces
that control drug absorption, transport and metabolism (Darwich
et al., 2010).
Herein the relative bioavailability between CR and IR formula-
tions of CYP3A substrates was investigated in order to understand
how the physicochemical, biochemical and pharmaceutical prop-
erties of a drug (or drug product) can affect its oral bioavailability.
Firstly, a literature survey was performed to collate clinical studies
in which the pharmacokinetics of CYP3A4 substrates were simulta-
neously investigated in both IR and CR formulations. Secondly, a
systematic analysis was performed to investigate the impact that
drug release characteristics and the drug-related physicochemical
34 A. Olivares-Morales et al. / European Journal of Pharmaceutical Sciences 67 (2015) 32–44and biochemical properties deﬁning oral bioavailability have on
oral drug absorption and CYP3A4-mediated intestinal ﬁrst pass
metabolism. This was performed using in silico PBPK M&S. The
aims of this study were to investigate possible mechanisms
involved in the observed differences in oral bioavailability between
IR and CR formulations by analysing the trends in fa, FG, and the
systemic exposure (AUC). In addition, an attempt was made to
identify the parameter space associated with the higher relative
bioavailability of drugs formulated as CR compared to their IR
counterparts and to correlate simulations with the observed clini-
cal data gathered from the literature search.2. Materials and methods
2.1. Literature survey
A literature survey was conducted using PubMed and Google
Scholar in order to identify studies in which the pharmacokinetics
of CYP3A4 substrates formulated as IR and CR was investigated.
The search was restricted only to those studies in which the phar-
macokinetic parameters of both formulations were investigated in
the same set of subjects, ideally healthy adult volunteers. In order
to avoid any possible food effects on the absorption parameters,
only studies for which the formulations were administrated in
fasted conditions were considered. The main pharmacokinetic
parameter of interest was the AUC. Whenever reported, the rela-
tive bioavailability between the IR and CR formulation, in terms
of the AUC ratio (CR/IR) and its 90% conﬁdence interval was
employed. Otherwise it was calculated employing an approxima-
tion of the Fieller’s Theorem (Fieller, 1954; Motulsky, 2010) using
the reported AUCs, only when both CR and IR formulations were
investigated in the same set of subjects. The detailed calculation
method is described in the Supplementary Material.2.2. Simulations and PBPK model
For the analysis of the impact of the controlled release formula-
tions on fa, FG and systemic exposure, a series of simulations were
conducted employing the Advanced Dissolution Absorption and
Metabolism (ADAM) model within the Simcyp population-based
simulator (Jamei et al., 2009b) Version 12 Release 2 (Simcyp Lim-
ited, Shefﬁeld, UK). The ADAM model is a PBPK absorption model
that integrates the drug physicochemical and biopharmaceutical
properties (e.g. release proﬁle, solubility, permeability, particle
size, afﬁnity for metabolic enzymes, etc.) and the human physiol-
ogy (e.g. gastric empting, intestinal transit times, GI ﬂuid volumes,
metabolic enzyme abundances, blood ﬂows, bile secretion, etc.)
and their variability (Jamei et al., 2009b, 2009c). Within the ADAM
model the anatomy of the human GI tract is represented by nine
consecutive segments (stomach, duodenum, jejunum 1 and 2,
ileum 1–4, and colon). Each segment is described as a smooth cyl-
inder with the anatomical and physiological characteristics of each
segment accounted for, i.e., ﬂuid dynamics, pH, bile salt concentra-
tion, surface area, blood ﬂows, gut wall mass and volume, etc. Drug
transit throughout the segments is modelled as ﬁrst order unidi-
rectional process, from the stomach to the colon. In each segment
the amount of drug is distributed between four different states:
drug in formulation, drug released (undissolved), drug dissolved,
and drug degraded in the lumen. The dissolution rate can either
be inputted from an in vitro dissolution proﬁle and/or estimated
from a built-in diffusion layer model (DLM), it is assumed that only
dissolved drug can be absorbed. Drug absorption into the gut wall
is modelled as a ﬁrst order process depending on the drug’s intes-
tinal permeability and the segment’s physiological characteristics.
When required, Michaelis–Menten kinetics can be used to modelcarrier mediated intestinal uptake and/or efﬂux. The intestinal
regional distribution pattern of a given transporter is incorporated
and is expressed relative to the abundance in the jejunum (Mouly
and Paine, 2003; Jamei et al., 2009c). It is also assumed that the
absorption from the stomach is negligible compared to the absorp-
tion in the small intestine and the colon. The drug is absorbed into
the enterocyte compartment, where enzymatic ﬁrst pass metabo-
lism can occur by either CYPs and/or UDP-glucuronosyltransferas-
es (UGTs), following Michaelis–Menten kinetics; with only the
drug’s free fraction (fraction unbound (fu)) being susceptible to
metabolism. Alternatively, the Qgut model (Yang et al., 2007) can
be employed for the estimation of the ﬁrst pass gut wall metabo-
lism. The distribution of CYPs and UGTs enzymes along the GI tract
is also incorporated in the ADAM model. The non-metabolized
fraction enters the portal vein by means of blood ﬂow limited pro-
cesses and subsequently enters the liver, where additional ﬁrst
pass metabolism can occur prior to reaching the systemic circula-
tion. A detailed description of the ADAMmodel within the Simcyp
population-based simulator can be found elsewhere (Jamei et al.,
2009b,2009c). The selection of the ADAM model was based on its
capability to simulate drug absorption and ﬁrst pass metabolism,
taking into account the factors that have an impact on these
processes.2.3. Study design and parameter selection
To investigate the impact of different formulations and the rel-
evant drug properties on fa, FG, and AUC a factorial study was
designed (Fig. 1). A set of ﬁve release proﬁles, representative of ﬁve
different formulations, were deﬁned by varying the release rate
constant (krel) from 0.096 h1 to 4.6 h1 in Eq. (1)
FrelðtÞ ¼ 1 ekrelt ð1Þ
where Frel(t) is the fraction of the dose released from the formula-
tion as a function of time (h). The ﬁve release proﬁles were repre-
sentative of two immediate release (IR) tablets and three
controlled release (CR) tablets. The proﬁles were designed to release
90% of the drug content within 0.5, 1, 6, 12 and 24 h, resulting in a
krel of 4.6, 2.3, 0.38, 0.19, and 0.096 h1, respectively (t90). Six drug-
speciﬁc parameters were selected based on their importance in
deﬁning oral bioavailability and were systematically modiﬁed to
generate a set of virtual compounds. The modiﬁed parameters
included: solubility (mg/mL); human jejunal effective permeability,
Peff (104 cm/s); maximal CYP3A4-mediated metabolic rate,
Vmax,CYP3A4 (pmol/min/mg microsomal protein); CYP3A4 afﬁnity,
Km,CYP3A4 (lM); maximal P-gp-mediated efﬂux rate, Jmax,P-gp
(pmol/min); and P-gp afﬁnity, Km,P-gp (lM). In addition, each
parameter was assigned ﬁve different values. Hence, the number
of virtual compounds amounted to 15,625. For each virtual com-
pound ﬁve simulations were carried out, one for each of the release
proﬁles described above, resulting in a total of 78,125 simulations
(57). The speciﬁc ranges for each parameter were derived from
the literature and were representative of the values obtained exper-
imentally. Unless otherwise stated, the values were representative
of approximately the 1st, 25th, 50th, 75th and 99th percentile of
the range reported in the selected references.
Aqueous solubility values were derived by rearranging the dose
number (Dn) equation (Amidon et al., 1995) into Eq. (2), and
employing the Dn values as reported by Benet et al. (2011), only
for the compounds for which the authors reported the experimen-
tal aqueous solubility. The dose employed for the estimation of the
solubility as function of the Dn was 30 mg. The reason for selecting
this dose was based on an exploratory study initially performed for
buspirone, where administered the dose for the CR formulation
was 30 mg (Sakr and Andheria, 2001a,2001b). The aforementioned
Fig. 1. Schematic representation of the study design tree. Values 1–5 in each circle
represent the different values that each parameter could take. ‘‘Sim’’ represent the
result of a simulation. Each result is a product of the combinations of the different
values of each parameter. The parameters are as follows: release rate constant (krel),
solubility (sol), apparent permeability in Caco-2 cells monolayers (Papp), maximum
metabolic rate by CYP3A4 (Vmax), substrate afﬁnity for CYP3A4 (Km), maximum
efﬂux rate by P-gp (Jmax) and substrate afﬁnity for P-gp (Km).
A. Olivares-Morales et al. / European Journal of Pharmaceutical Sciences 67 (2015) 32–44 35procedure allowed us to evaluate the impact of solubility, regard-
less of the selected dose.
Solubility ¼ Dose=250 ml
Dn
ð2Þ
Human jejunal effective permeability was obtained from the
report by Lennernas (2007). Peff values were converted to apparent
passive permeability in Caco-2 cell monolayers (Papp,Caco-2
(106 cm/s)) employing the relationship reported by Sun and co-
workers (Eq. (3)) (Darwich et al., 2010; Sun et al., 2002). This con-
version was performed to account for the passive component of the
intestinal permeability described within Peff, whereas the active
component was explicitly accounted by the simulations of the P-




The use of the aforementioned correlation entails some limita-
tions mainly due to the limited number of compounds on which it
is based (n = 13), the observed mild correlation (r2 = 0.85), and the
associated wide prediction intervals. Thus, a note of caution is rec-
ommended before its application. Nevertheless, for the work
performed herein, once the Papp,Caco-2 range was obtained using
the aforementioned correlation, the Papp,Caco-2 values were con-verted back to Peff in the ADAM model, using the same equation.
This was done in order to estimate the absorption rate constant
(ka,i) in each of segments of the ADAM model (Jamei et al., 2009c).
Enzyme kinetic parameters, i.e., intrinsic metabolic clearance
(CLint), Vmax and Km, for CYP3A4-mediated metabolism in human
liver microsomes (HLM) were obtained from the review by Bu for
113 compounds (Bu, 2006). Reported Vmax and Km values were
employed directly as no correlation was observed between them.
The CYP3A4-mediated intrinsic metabolic clearance was calculated
from the ratio between the Vmax and Km, assuming linear condi-
tions (Vmax/Km). Vmax and Km values were limited, when possible,
to those that in combination generated CLint,CYP3A4 values within
the CLint,CYP3A4 range reported by Bu (2006).
Transporter kinetic parameters, i.e., Jmax and Km, for the P-gp-
mediated efﬂux in Caco-2 cell monolayers were obtained from
the work of Troutman and Thakker (2003) for 8 different P-gp
substrates. In the same way as for the CYP3A4 kinetic parameters,
P-gp-related parameters were treated as independent, and the
intrinsic clearance (CLint,P-gp(efﬂux)) was calculated from the ratio
between Jmax and Km assuming linear conditions. Limitations were
applied as described above to match the reported CLint,P-gp(efﬂux)
values (Troutman and Thakker, 2003).
2.4. Model assumptions and simulations
A Simcyp ‘‘compound ﬁle’’ was created based on the reported
physicochemical characteristics, protein binding and blood-to-
plasma ratio for the compound buspirone (Gammans et al., 1986;
Gertz et al., 2011; Shibata et al., 2002). The ‘‘compound ﬁle’’ was
then modiﬁed and used as a template to generate a set of virtual
compounds from the combinations of the aforementioned param-
eters. The ionic class of the virtual compounds was set to be neu-
tral in order to simplify the analysis and to reduce the number of
combinations that could be derived from accounting for the differ-
ent ionic classes. The drug’s dissolution rate was estimated using
the diffusion layer model built-into the Simcyp ADAM model,
where the drug was assumed to be a monodispersed powder with
an initial particle radius of 30 lm. Peff values were estimated from
the calculated Papp,Caco-2 values using the default method in the
Simcyp simulator for passively absorbed drugs (Sun et al.,
2002), Peff was kept constant throughout all the intestinal seg-
ments. Elimination was assumed to occur only by means of
CYP3A4-mediated metabolism, both in the liver and the GI tract,
which was estimated from the aforementioned enzyme kinetics
parameters of CYP3A4. The fraction of drug unbound in the entero-
cytes (fu,gut) was assumed to be 1 as per Yang et al. (2007). The rest
of the parameters were kept as Simcyp default values. The input
parameters are summarized in Table S1 of the Supplementary
Material.
The virtual trials were simulated assuming a representative
population. The values employed were those from the ‘‘healthy
volunteers’’ population library within Simcyp, assuming no vari-
ability for the system parameters. A ‘‘minimal’’ PBPK model was
used to describe the disposition and systemic elimination of the
simulated compounds (Rowland Yeo et al., 2010). The oral dose
was set to 30 mg, administered under fasted conditions together
with 250 mL of water; with sampling up to 36 h post dose (Sakr
and Andheria, 2001a,2001b). Simulations were carried out using
the Simcyp Batch processor on a Dell OptiPlex 7010 PC (Intel Core
i7-3770, 16 GB Ram) running Microsoft Windows 7 Enterprise
(Dell Corp. Ltd., Berkshire, UK).
2.5. Data analysis
In order to analyse the simulated data the study tree was sub-
categorized into the four classes described in the BCS, thus leading
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78,125 to 12,500) by limiting the values for solubility and perme-
ability from ﬁve to two values each. Selection of the solubility and
permeability values was based on the BCS cut-off criteria for high/
low soluble and permeable compounds. Solubility was considered
high if its corresponding Dn was less than 1, whereas for a Dn equal
or greater than 1, solubility was considered as low (Amidon et al.,
1995). Permeability was considered high if the calculated fraction
absorbed was equal or greater than 0.9, and a value below 0.9
was considered as low permeability (U.S. Food and Drug
Administration, 2000). The fraction absorbed was calculated
employing Eq. (4) (Amidon et al., 1995; Sinko et al., 1991)
f a ¼ 1 e
2Peff
R TSI ð4Þ
where R is the mean radius of the small intestine (1.75 cm) and TSI is
the mean transit time in the small intestine (3.32 h) (Lennernäs
et al., 1992; Yu et al., 1996).
Data analysis was carried out using Matlab 2013a (The Math-
works Inc., Natick, MA, USA). The analysis was focused on the
impact of the release rate constant (krel), and the drug speciﬁc
parameters on the simulation outcome (fa, Fg and AUC). Several
scenarios were evaluated for the impact of both CYP3A4 and P-
gp clearance employing a ‘‘one-at-a-time’’ method, i.e., ﬁxing most
of the parameters and varying the parameters of interest. These
were accomplished by either ﬁxing Vmax,CYP3A4/Jmax,P-gp, and vary-
ing Km (CYP3A4/P-gp) or vice versa. The scenarios evaluated are
described in Table 1.
Amongst the scenarios described in Table 1, the cases in which a
CR formulation showed higher relative bioavailability (Frel) than
the corresponding IR formulation were investigated in further
detail. Frel was calculated using Eq. (5)
Frel ¼ AUCMRAUCIR  100 ð5Þ
where AUCIR was the AUC of the IR formulation with a krel of 4.6 h1
and AUCMR was the AUC of any of the other formulations evaluated.
The simulations were compared, in terms of release characteristics,
relative bioavailability and metabolic clearance, with the observed
data derived from the literature search. The latter was performed
only for compounds with similar physicochemical properties as
the simulated compounds and for those for which the main meta-
bolic enzyme was CYP3A4, i.e., the CYP3A4 is responsible for 50%
or more of the compound’s metabolic clearance (fmCYP3A4P 0.5).
Whenever possible the release characteristics of the literature com-
pounds were derived from the in vitro release proﬁles where the
corresponding krel was estimated according to its t90 (Eq. (6)) other-
wise these were approximated based on the information described
in the product label and/or clinical studies. With regards to the met-
abolic clearance, in order to avoid any possible underpredictionsTable 1
Different scenarios evaluated for CLint,CYP3A4 CLint,P-gp for all BCS classes as a function of re
Scenario Description CLint,CYP3A4 (lL/min/mg
Vmax (pmol/min/mg)
Ia CYP3A4 (m) Fixed (500)
Ib CYP3A4 (m) Variable
IIa CYP3A4 (h) Fixed (2500)
IIb CYP3A4 (h) Variable
IIIa P-gp (m) –
IIIb P-gp (m) –
IVa CYP3A4 (h) & P-gp (m) Fixed (2500)
IVb CYP3A4 (h) & P-gp (m) Variable
Va CYP3A4 (h) & P-gp (m) Fixed (2500)
Vb CYP3A4 (h) & P-gp (m) Fixed (2500)
(h), high; (m), medium.resulting from the use of the mean in vitro metabolic data
(Hallifax et al., 2010; Hallifax and Houston, 2012) the intrinsic met-
abolic clearance in HLM was back calculated from the in vivo sys-
temic clearance employing either the well-stirred model
(Rowland et al., 1973) or the dispersion model (Roberts and
Rowland, 1986). The details of the calculations are described in
the Supplementary Material.
krel ¼ ln 10t90 ð6Þ3. Results
The literature survey was successful in retrieving and identify-
ing 17 studies of 11 different compounds that met the inclusion
criteria (Fig. 2). The compounds were identiﬁed to belong to classes
1–3 of the BCS. Based on the 17 studies uniquely identiﬁed in this
investigation, 23 data points were derived for the analysis of the
relative bioavailability between CR and IR formulations, 8 of which
were directly given in the reports whilst the rest were calculated
from the information given in the reports. The detailed information
in terms of AUC ratios, 90% conﬁdence intervals and their refer-
ences are shown in Table S2 of the Supplementary Material.3.1. Parameter range and values
The simulated parameters and their ranges are summarized in
Table 2. Solubility varied from 105 to 104 mg/mL as derived from
Eq. (2). The range of solubility values was truncated to a minimum
of 0.001 mg/mL and a maximum of 100 mg/mL in order to improve
the computational performance of the simulations. Human Peff ran-
ged from 0.04 to 10  104 cm/s. Calculated Papp,Caco-2 values (Eq.
(3)) varied from 0.01 to 80  106 cm/s, covering the range from
low to highly permeable compounds (Lennernas, 2007). The
Vmax,CYP3A4 and Km,CYP3A4 range varied from 1 to 10,000 pmol/min/
mg microsomal protein and 1–10,000 lM, respectively. Jmax,P-gp
and Km,P-gp ranges were 1–1500 pmol/min and 1–2,000 lM,
respectively.3.2. Cut-off values for BCS classiﬁcation
The values that deﬁned the limits for high and low solubility
were 10 mg/mL (Dn = 1.2) and 1.0 mg/mL (Dn = 0.12), respectively.
Likewise, the value for high permeability was 5  106 cm/s
(fa  0.89) whereas for low permeability, the value was
0.5  106 cm/s (fa  0.34). For both solubility and permeability,
the selected cut-off values coincided with the 25th and 50th per-
centile of their selected range (values 2 and 3 in Fig. 1).lease rate.
) CLint,P-gp (lL/min)
Km (lM) Jmax (pmol/min) Km (lM)
Variable – –
Fixed (50) – –
Variable – –
Fixed (1) – –
– Fixed (300) Variable
– Variable Fixed (150)
Variable Fixed (300) Fixed (150)
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Fig. 2. Analysis of the relative bioavailability between CR and IR formulations of
CYP3A4 substrates. The markers represent the mean relative bioavailability and the
lines represent the 90% conﬁdence intervals. The marker shape and colour
represents the BCS class for each compound: class 1 (blue circle), class 2 (green
square) and class 3(red triangle). (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
Table 2
Evaluated parameters and values.
Parameter Value
1 2 3 4 5
krel (h1) 4.6 2.3 0.38 0.19 0.096
Solubility (mg/mL) (Dn) 0.001 0.1 1 10 100
Papp,Caco-2 (106 cm/s) (120) (12) (1.2) (0.12) (0.012)
0.01 0.5 5 10 80
Vmax,CYP3A4 (pmol/min/mg) 1 100 500 2500 10,000
Km,CYP3A4 (lM) 1 10 50 100 10,000
Jmax,P-gp(efﬂux) (pmol/min) 1 30 300 500 1500
Km,P-gp(efﬂux) (lM) 1 50 150 300 2000
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In general, a reduction in release rate, i.e., changing from an IR
formulation to a CR formulation, was associated with a decrease in
AUC for a majority of the CYP3A4 substrates (Figs. 3A and S1A–
S3A). However, in certain cases, the AUC either remained constant
as compared to the IR formulation or increased when the CR for-
mulations were employed; dependent on both BCS class and
CLint,CYP3A4. When Vmax,CYP3A4 was kept ﬁxed (scenarios Ia and IIa
in Table 1), the increase in exposure was only observed for BCS
class 1 CYP3A4 substrates with CLint,CYP3A4 values equal to or
greater than 250 lL/min/mg (Figs. 3A and S1A). A similar situation
was observed when Km,CYP3A4 was ﬁxed to the ‘medium’ value (sce-
nario Ib in Table 1) though the CLint,CYP3A4 necessary to observe a
similar change in exposure was reduced to 50 lL/min/mg
(Fig. S2). The use of a low Km,CYP3A4 in scenario IIb, i.e., high afﬁnity
for CYP3A4, resulted in a similar outcome. However, the AUC also
remained constant for CR formulations of highly cleared(CLint,CYP3A4P 2500 lL/min/mg) BCS classes 2 and 3 drugs
(Fig. S3A).
For scenarios Ia-IIb the BCS classiﬁcation had an effect on fa,
where fa decreased when moving from BCS class 1 to class 4.
CLint,CYP3A4 had no impact on fa. In addition, CR formulations sys-
tematically displayed lower fa compared to the IR formulations,
where the fa was reduced as a consequence of a reduced krel. A sim-
ilar trend was observed for almost all of the scenarios evaluated in
Table 1. The magnitude of the differences in fa, as a result of chang-
ing krel, was higher for highly permeable compounds (BCS classes 1
and 2). On the contrary, FG showed an opposite trend as compared
to that of fa. The CR formulations showed higher FG than their IR
counterparts, the increase was inversely related to the decrease
in drug release rate. The magnitude of the increase in FG was
dependent on the CLint,CYP3A4 and was typically observed for virtual
compounds with CLint,CYP3A4 equal to or greater than 200 lL/min/
mg. For compounds displaying a low afﬁnity to CYP3A4, the differ-
ences in FG were almost imperceptible (Figs. 3B and S1B–S2B). On
the contrary, for compounds with high afﬁnity for CYP3A4, the dif-
ference in FG as a function of both release rate and CLint,CYP3A4 was
highly marked (scenario IIb; Fig. S3B).3.4. Simulations: P-gp substrates
For the simulated P-gp substrates (scenarios IIIa and IIIb in
Table 1) the relationship between AUC and drug release was simi-
lar to that observed for the CYP3A4 substrates. Nevertheless, irre-
spectively of the values for CLint,P-gp, the AUC decreased as the
release rate was reduced, this was more pronounced for low solu-
ble compounds (BCS classes 2 and 4; Figs. 4A and S4A). For BCS
class 1 compounds, CLint,P-gp values between 0.007 and 30 lL/min
had almost no impact on the AUC. However, a decrease in the
AUC was observed when CLint,P-gp was set to 300 lL/min (Figs. 4A
and S4A). No differences were noticeable when ﬁxing either
Jmax,P-gp or Km,P-gp. As for the CYP3A4 substrates, the fa was lower
for CR formulations than for their IR counterparts, and decreased
as the release rate decreased. On the contrary to what was seen
for CYP3A4 substrates, altering CLint,P-gp had an impact on the fa,
where the impact on fa was dependent upon the CLint,P-gp values
and BCS classiﬁcation. The fa of BCS class 2 compounds was the
most sensitive to changes in CLint,P-gp (Figs. 4B and S4B). Since
the aforementioned compounds were not subject to metabolism,
neither the release rate nor the CLint,P-gp had an impact on FG.3.5. Simulations: CYP3A4 and P-gp substrates
Scenarios IVa–Vb in Table 1 describe the simulations carried out
for virtual compounds with overlapped afﬁnity for both CYP3A4
and P-gp. When CLint,CYP3A4 was varied, and using a ﬁxed CLint,P-gp
(2 lL/min), no signiﬁcant differences were observed between the
new AUC trend compared to the trend observed for CYP3A4 sub-
strates only (Figs. 5A and S5A). A similar outcome was obtained
when the analysis was performed from the P-gp point of view,
i.e., varying CLint,P-gp and using a ﬁxed CLint,CYP3A4 (2500 lL/min/
mg); the observed trends were similar to that for P-gp substrates
alone (Figs. S6–7B). Likewise, both fa and FG followed almost a sim-
ilar pattern as the observed for CYP3A4 or P-gp substrates only
(Figs. 5B and S5–7B). Although the overall trend remained the
same, subtle changes were observed in the trends of fa and FG in
response to changes in the CLint,CYP3A4 or CLint,P-gp, respectively;
an increase of CLint,CYP3A4 led to an increase in fa (Fig. 5B), likewise,
an increase in CLint,P-gp resulted in a small increase on the FG
(Figs. S6–7B). These changes were dependent of both release rate
and BCS classiﬁcation, as the increase in fa was more prominent
for IR formulations of BCS class 2 compounds (Figs. 5B and S5B),
Fig. 3. Impact of release rate (formulation) and CLint,CYP3A4 on AUC (A), fa and FG (B) for non-P-gp substrates. Vmax,CYP3A4 was ﬁxed at 2500 pmol/min/mg whereas the Km,CYP3A4
was varied (scenario IIa in Table 1). For plots A and B, the subplots represent the different BCS classes (1–4), whereas the symbols in each plot represent different CLint,CYP3A4
values: upper triangle (2500), circle (250), square (50), diamond (25), and lower triangle (0.25). For the plots in the right hand side (B), the green lines and open symbols
represent FG, whereas the black lines and ﬁlled symbols represent the fa. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
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formulations of BCS class 1 compounds (Fig. S6A).
3.6. Relative bioavailability of CYP3A4 substrates
Analysis of the relative bioavailability (Frel) of CR formulations
showed that highly (CYP3A4) cleared BCS class 1 simulated com-
pounds could display up to a 220% higher Frel compared to the IR
formulations. When the trends for the simulations were compared
with similar compounds derived from the literature survey, i.e.,
BCS class 1 and mainly CYP3A4 cleared, there was a very good
agreement between the simulated Frel and the observed data
(Fig. 6). The back-calculated CYP3A4 clearance values (HLM) from
the in vivo systemic clearance are reported in Table S3 of the Sup-
plementary Material.
4. Discussion
4.1. Analysis of the relative bioavailability between CR and IR
formulations of CYP3A4 substrates
Due to the selected inclusion criteria for the search, the analysis
was limited only to 11 different compounds (Fig. 2). A larger set of
drugs could have been included for this analysis if, for instance, the
calculations of relative bioavailability were performed between
different subjects and groups, i.e., the IR data was taken from one
study whereas the CR data was taken from a separate study. How-
ever, this would have confounded the impact of the formulation
with the inter-individual variability of the kinetics, leading to var-
iable Frel. Therefore these studies were not considered. Of the total
drugs investigated, only three drugs formulated as CR showed sta-
tistically signiﬁcant higher relative bioavailability than their IRformulations (simvastatin, buspirone and oxybutynin). In contrast,
a majority of the drugs showed either similar or lower relative bio-
availability when formulated as CR. Judging from the BCS point of
view an a priori trend for either higher of lower Frel was not clear.
For instance CR formulations of ﬂuvastatin (BCS class 1) and simva-
statin (BCS class 2), both highly permeable compounds, showed
opposite results in terms of Frel (Fig. 2). Whereas CR formulations
of low permeable compounds, such as propiverine and gepirone
(both BCS class 3), showed similar Frel to their IR formulations.
Therefore this justiﬁed the use of more mechanistic and multivar-
iate models such as PBPK for M&S purposes in order to accommo-
date several factors inﬂuencing the observed differences.
4.2. Impact of release rate on oral drug absorption and bioavailability
A general trend towards a reduction in drug exposure (AUC)
was observed in simulations when varying the release rate, i.e.,
moving from an IR formulation to a CR formulation. These results
were anticipated as, in general the CR formulations are intended
to release the majority the drug content further distally in the
intestine (e.g., distal ileum and colon), where the distal regions of
the GI tract provides unfavourable conditions for drug absorption
compared to the upper regions of the small intestine (Lennernas,
2014a; Schiller et al., 2005; Sutton, 2009; Tannergren et al.,
2009). This assumption is supported by the observed decrease in
fa when switching from IR to CR formulations (Figs. 3–5B). Interest-
ingly the decrease in fa was observed for all the scenarios evaluated
irrespectively of BCS class, CYP3A4 clearance, and/or P-gp efﬂux.
These results are in line with the work by Tannergren et al.
(2009), where they investigated the colonic absorption and bio-
availability of several compounds, compared to that in upper
regions of the GI tract. For BCS class 1 compounds, the relative
Fig. 4. Impact of release rate (formulation) and CLint,P-gp on AUC (A), fa and FG (B) for non CYP3A4 substrates. Jmax,P-gp was ﬁxed at 300 pmol/min whereas the Km,P-gp was
varied (scenario IIIa in Table 1). For plots A and B, the subplots represent the different BCS classes (1–4), whereas the symbols in each plot represent different CLint,P-gp values:
upper triangle (300), circle (6), square (2), diamond (1), and lower triangle (0.15). For the plots in the right hand side (B), the green lines and open symbols represent the FG,
whereas the black lines and ﬁlled symbols represent the fa. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
Fig. 5. Impact of release rate (formulation), CLint,CYP3A4, and CLint,P-gp on AUC (A), fa and FG (B). Vmax,CYP3A4 was ﬁxed at 2500 pmol/min/mg whereas the Km,CYP3A4 was varied
(scenario Va in Table 1). CLint,P-gp was ﬁxed to 2 lL/min. For plots A and B, the subplots represent the different BCS classes (1–4), whereas the symbols in each plot represent
different CLint,CYP3A4 values: upper triangle (2500), circle (250), square (50), diamond (25), and lower triangle (0.25). For the plots in the right hand side (B), the green lines and
open symbols represent the FG, whereas the black lines and ﬁlled symbols represent the fa. (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
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Fig. 6. The impact of release rate and CLint,CYP3A4 on the relative bioavailability (%) for BCS class 1 compounds (see methods section). Different release rates (krel) represent
different formulations. Km,CYP3A4 was ﬁxed to 1 lMwhereas Vmax,CYP3A4 was variable. For the IR control (krel = 4.6 h1) Frel was 100%. The colour bar indicates the Frel values (%)
represented in the 3D surface. The circles and line represent the mean Frel and its 90% conﬁdence interval for BCS class 1 compounds mainly cleared by CYP3A4
(fmCYP3A4P 0.5): buspirone sustained release (BUSP F1), buspirone extended release (BUSP F2), oxybutynin extended release (OXYB), quetiapine extended release (QETP) and
cyclobenzaprine extended release (CBZP).
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the upper regions of the intestine. In this study the Frel between
the IR and CR formulations for low CYP3A4 afﬁnity BCS class 1
compounds, varied between 49% and 80% (mean: 66%) in agree-
ment with the value reported by Tannergren et al. (2009)
(FrelP 70%). On the other hand, the simulated relative absorption,
fa,rel, for the same compounds varied between 66% and 88% (mean:
72%). Where Tannergren, and co-workers, reported values between
39% and 127% with a mean of 82% (Tannergren et al., 2009). For
BCS classes 3 and 4, however, Tannergren found a low Frel in the
colon (Frel < 50%). In the current simulation study, Frel varied
between 42% and 68% for BCS class 3 compounds, and 23% and
53% for BCS class 4 compounds, whereas fa,rel varied between 58–
76% and 34–61% for BCS classes 3 and 4 compounds, respectively.
The latter might indicate an overestimation of the absorption for
BCS classes 3 and 4 compounds in our simulations. This could be
due to an overestimation of colonic permeability, in our study
we employed a constant Peff value throughout all intestinal seg-
ments within the ADAM model, however this might not be neces-
sarily the case. It has been suggested that the reduced surface area
and increased number of tight junction in the colon could limit the
permeability of passively absorbed compounds (Lennernas,
2014a), thus permeability could vary along the GI tract, in particu-
lar for the colon. This was not taken into account in the simula-
tions, and could lead to this possible overestimation of fa,rel.
Nevertheless, more data has been sort in order to support the exis-
tence of a differential permeability along the GI tract (Lennernas,
2014b). Another possible source of error that might explain those
differences was the use of Eq. (3) to correlate Papp,Caco-2 with Peff
(and vice versa). This equation is associated with large prediction
intervals and therefore this can affect the Peff predictions (Sun
et al., 2002). However this is unlikely to affect the overall outcomeof this study as the values Papp values were subsequently
back-transformed into Peff using the same equation by the ADAM
model.
A similar overestimation could arise for colonic solubility. In the
present study all compounds were treated as neutral and therefore
regional differences in the intestinal pH, which are accounted for in
the ADAM model, did not affect intestinal solubility of the com-
pounds. This may in particular lead to an overestimation of colonic
solubility of basic compounds, whereas an opposite situation can
occur for acidic compounds, for which the solubility is higher in
the upper regions of the GI tract. There are also many in vivo factors
that might contribute to the possible under/overestimation of drug
dissolution and solubility within the GI tract. For instance the over-
simpliﬁed composition of the small intestinal and colonic ﬂuids in
available PBPK absorption models, as well as the actual ﬂuid vol-
umes available to dissolve the drug might affect such estimations
(Sjogren et al., 2014).
Furthermore, several biopharmaceutical and physicochemical
properties, known to inﬂuence drug absorption, were not taken
into account in this study, i.e. particle size and its distribution;
excipients; and in particular the drug release mechanism, which
was oversimpliﬁed in this study; just to name a few (Martinez
and Amidon, 2002). Consideration of such factors would have sig-
niﬁcantly increased the number of simulations to be performed,
thus complicating any subsequent analysis. Those simulations
were out of the scope of this work.
4.3. Understanding of the higher relative bioavailability observed for
CR formulations of CYP3A4 substrates
One of the main goals of this work was to identify the parameter
space in which a drug, formulated as CR, would display higher
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The above results clearly indicated absorption – fa – to be reduced
for all the CR formulation as compared to the IR formulations.
Still, in the case of the simulated CYP3A4 substrates, the reduction
in fa seemed to be compensated by an increase in FG (Figs. 3B and
S1B–S3B), that is, a reduction in the CYP3A4-mediated ﬁrst pass
intestinal metabolism. For some of the simulated compounds, this
compensation was translated into similar exposure levels of CR for-
mulations as compared to IR. The proposed explanation is based on
the distribution of the CYP3A abundance along the GI tract. As dis-
cussed previously in this manuscript, the CYP3A enzymes decrease
towards the distal regions of the human GI tract (Berggren et al.,
2007; Paine et al., 1997; Zhang et al., 1999), this pattern is taken into
account in the ADAM model. As a result, when a CR formulation
releases its drug content into the distal regions of the intestine, the
drug would encounter less CYP3A enzymes on its way towards the
portal circulation, thus reducing the CYP3A-mediated intestinal ﬁrst
pass metabolism. In this study the impact on the AUC was however
only noticeable for highly permeable (BCS classes 1 or 2) and highly
cleared drugs (CLint,CYP3A4P 250 lL/min/mg). This seems reason-
able as the differences in absorption between CR and IR formulation,
for BCS classes 2 and 4 compounds, would be too high to be
compensated by a reduction in the intestinal ﬁrst pass metabolism.
Nevertheless, a similar exposure level as the IR formulation was
observed for the CR formulations for some of the BCS class 3
compounds (high CLint,CYP3A4P 2500 lL/min/mg). This could be a
product of the aforementioned overestimation in absorption. BCS
class 1 compounds, on the other hand, aremore likely to be absorbed
indistal regionsof theGI tract (Tannergrenet al., 2009). Thus, for this
type of compounds, the reduction in intestinal metabolism could
lead to AUC levels higher than that observed for IR formulations
(Figs. 3A and S3A).
A relative bioavailability of up to 220% was observed for the
simulated CR formulations of highly CYP3A4-cleared compounds
(CLint,CYP3A4P 2500 lL/min/mg) (Fig. 6). These results were in
good agreement with the clinical observations for CR release for-
mulations, for buspirone, oxybutynin, quetiapine and cyclobenza-
prine, where the increase in relative bioavailability in the CR
formulations was dependent upon an apparent reduction in met-
abolic clearance of the aforementioned compounds. The use of
in vivo data for the determination of the in vitro intrinsic clear-
ance for the analysis in Fig. 6 seemed justiﬁed as the in vitro val-
ues would have underpredicted the in vivo clearance for
oxybutynin and buspirone. The in vitro clearance, varied between
268 and 442 lL/min/mg (Gertz et al., 2011; Zhu et al., 2005) for
buspirone, and 78–278 lL/min/mg for oxybutynin (Mizushima
et al., 2007; Yaich et al., 1998), whereas the value determined
from the in vivo clearances (Table S3) were 5454 lL/min/mg
and 2932 lL/min/mg for buspirone and oxybutynin, respectively.
This underprediction was also observed, to a lesser extent, for
cyclobenzaprine, whereas for quetiapine an in vitro value similar
to the in vivo value was observed (Table S3). The mechanisms
behind said underpredictions when using human liver micro-
somes are still unknown; however it has been attributed to fac-
tors such as the ionization, binding to plasma proteins, and
clearance model inaccuracies (Berezhkovskiy, 2011; Hallifax
et al., 2010; Hallifax and Houston, 2012; Poulin, 2013; Poulin
et al., 2012). Simvastatin (BCS class 2) represent an interesting
case that was not in agreement with the simulated Frel across
the deﬁned parameter space. Even though simvastatin is classi-
ﬁed as BCS class 2 the CR formulation showed 2–3-fold higher
relative bioavailability that the IR formulation. One of the reasons
for such disagreement with the simulated data was the use of an
enabling CR formulation in one of the simvastatin studies
(Tubic-Grozdanis et al., 2008). The formulation employed in theaforementioned study contained a mixture of gelatine and leci-
thin intended to improve the wettability of simvastatin in the
formulation and promote the formation of microemulsions or
even micelles, thus improving simvastatin’s dissolution. In fact,
the solubility of simvastatin was increased more than 5000 times
when it was embedded in the mixture of gelatine and lecithin
(Tubic-Grozdanis et al., 2008). It is not clear whether the CR
formulation employed in the study by Jang et al. (2010) used
the same approach to increase the solubility of simvastatin. Yet,
the exposure of the CR formulation was similar to that of
Tubic-Grozdanis et al. (2008).
Another factor that might have inﬂuenced the observed differ-
ences in simvastatin’s exposure between IR and CR formulations
can be the fact that simvastatin is a prodrug that is converted to
simvastatin acid (the active form) in vivo (Prueksaritanont et al.,
2005). This process can occur by means of chemical and enzymatic
hydrolysis in both the gut wall and lumen, therefore differences
the enzyme levels along the gut wall membrane could explain
some of the observed differences in simvastatin’s exposure
(Alvarez-Lueje et al., 2005; Prueksaritanont et al., 2005; Satoh
et al., 2002). However, due to the similar exposure observed for
simvastatin acid between the IR and CR formulations, we believe
that these differences are predominately due to differences in the
CYP3A-mediated metabolism of simvastatin (Jang et al., 2010;
Tubic-Grozdanis et al., 2008)
Another aspect of this simulation study that may result in dis-
crepancies between simulated and observed data is the attempt to
describe a hypothetical BCS class 1 drug. However, the physiochem-
ical, biopharmaceutical, and afﬁnity properties employed herein
were not necessarily intended to represent those for the drugs used
for the comparison (i.e., oxybutynin, buspirone, etc.). Finally, in our
study, the fraction of drug unbound in the enterocyteswas assumed
to be 1. This assumption can affect FG estimations, as only the free
drug concentration in the enterocyte would be available for metab-
olism (Darwich et al., 2010; Heikkinen et al., 2012; Sinha et al.,
2012). This parameter is highly sensitive and this might affect the
results of the simulations when there is binding to the enterocytes
(Gertz et al., 2010; Yang et al., 2007). Nevertheless, this was not
the case, as the simulations performed herein were not meant to
represent any particular compound, rather they were representa-
tive of hypothetical cases, and thus the CLint,CYP3A4 range should be
considered as an unbound intrinsic clearance.4.4. Impact of the intestinal P-gp distribution and possible CYP3A4/P-
gp interplay on the bioavailability of CR formulations
The results for the simulated P-gp substrates were consistent
with the previous work by Darwich et al. (2010). In general both
absorption and exposure were decreased when CLint,P-gp was
increased. No impact on FG was observed as function of the
CLint,P-gp, in this scenario no intestinal metabolism was considered.
In addition, no signiﬁcant differences in terms of absorption and
exposure were observed between the IR and CR formulations as
product of variable P-gp clearance (Fig. 4).
When the analysis was performed on compounds with over-
lapped afﬁnity for both CYP3A4 and P-g, no signiﬁcant differences
were observed in the trend for AUC compared to that of simulated
CYP3A4 or P-gp substrates alone (Fig. 5). In the same line, only
minor differences in the trends for fa and FG were observed. These
subtle differences might be an indication of a possible competition
between CYP3A4 and P-gp for the substrate in the enterocyte com-
partments within the ADAM model. However, the reasons for such
differences are not clear yet. Further discussion about these results
is included in Sections 5 and 6 of the Supplementary Material.
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development
Previous multi-scale studies have investigated the complex
interplay between the factors governing drug absorption and intes-
tinal ﬁrst pass metabolism and absorption such as the study by
Darwich et al. (2010), using the same ADAM model, or the study
by Heikkinen et al. (2012) using the Advanced Compartmental
Absorption and Transit (ACAT) model in Gastroplus™. Neverthe-
less, to our understanding, this is the ﬁrst study that has investi-
gated the impact of the release characteristics from the
formulation on oral bioavailability, specially focused on the inter-
play between the physicochemical, biopharmaceutical and bio-
chemical properties.
From a biopharmaceutics point of view, there are an increasing
number of examples of the use of PBPK models for the optimiza-
tion of new dosage forms, in particular for CR formulations. Some
of these examples have recently been reviewed by Brown et al.
(2012). The use of PBPK models for the evaluation of the impact
of biopharmaceutical properties on absorption has recently been
encouraged by the regulatory agencies such as by the United States
Food and Drug Administration (Zhang and Lionberger, 2014). In
addition, our study provides a systematic analysis of the available
data on the relative bioavailability of CYP3A4 substrates as well as
the impact of drug- and formulation-speciﬁc factors on the oral
bioavailability. The outcome of this study can be considered as a
ﬁrst step in the line of providing examples of possible applications
of PBPK M&S in the formulation development process, in particular
for the evaluation of the possible impact of controlled release dos-
age forms on the drug candidate’s absorption and bioavailability.
This applies in particular for drugs candidates that are considered
as CYP3A4 substrates; however more work is needed in order to
fully validate this approach. Due to the complexity of the analysis,
we simpliﬁed several aspects that would have a clear impact on
predicted Frel. One of them was to assume a virtual reference
human, thus eliminating the inter-individual variability on the
physiological factors that inﬂuence drug absorption (Jamei et al.,
2009a).5. Conclusion
A factorial sensitivity analysis was performed for the investiga-
tion of the differences between immediate release and controlled
release formulations on drug absorption, ﬁrst pass metabolism
and systemic exposure. This was complemented with a literature
survey of the observed differences in oral bioavailability of CR for-
mulations of CYP3A4 substrates. The use of a PBPK absorption
model allowed the simultaneous consideration of both formulation
and drug-speciﬁc properties. In general, a reduced absorption was
observed when employing a controlled release formulation. The
results matched previous observations made for colonic absorption
(Tannergren et al., 2009). However, in some cases the reduction in
fa was compensated by a reduction in intestinal metabolism, thus
leading to a net increase in systemic exposure. This increase was
both permeability and CYP3A4-afﬁnity dependent. In addition, CR
formulations of highly CYP3A4-cleared compounds were more
likely to display higher relative bioavailability than the IR formula-
tions. The simulations were in agreement with the observed clini-
cal data for a number of CYP3A4 substrates. This study provided
further support to the hypothesis that the observed higher relative
bioavailability of CR formulations of highly cleared CYP3A4 could
be due to differences in the intestinal ﬁrst pass metabolism. The
outcome of this simulation study can be taken as a ﬁrst step, as
drug-speciﬁc simulations are required in order to fully support
the PBPK approach for investigation of these metabolic andabsorption differences. For P-gp substrates that were not subject
to ﬁrst-pass metabolism, no clear differences between the CR and
IR formulation were observed. Finally, an interplay between
CYP3A4 and P-gp was observed for IR formulations, however, more
data is needed to investigate the mechanism of such phenomena.
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